This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

AbbVie To Present Data On Investigational Anti-Cancer Compounds At American Society Of Clinical Oncology Annual Meeting

Stocks in this article: ABBV

NORTH CHICAGO, Ill., May 15, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, Chicago.  Data being presented include the results from two clinical trials evaluating the safety and efficacy of ABT-199, a BCL-2 selective inhibitor, in chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL).

Meeting abstracts are available today at http://chicago2013.asco.org/abstracts.

"These presentations further solidify our commitment to addressing the unmet need for new therapies that can improve on current treatment options for patients with cancer," said Gary Gordon, M.D., divisional vice president, oncology clinical development, AbbVie. "With our pioneering research, we are breaking new ground in some of the most widespread and difficult-to-treat cancers."

Presentation Details:

ABT-199

  • Updated Results of a Phase I First-In-Human Study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL); J.F. Seymour, et al.; Abstract 7018; Poster Discussion Session; June 1, 2013; 8:00 a.m.-12:00 p.m.
  • Updated Results of a Phase I First-In-Human Study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory (R/R) non-Hodgkin's Lymphoma (NHL); M.S. Davids, et al.; Abstract 8520; Oral Presentation; June 3, 2013; 11:30 a.m.-1:30 p.m.

Elotuzumab

  • A Phase I/II Study of Elotuzumab (Elo) plus Lenalidomide/Dexamethasone in Relapsed/Refractory (R/R) Multiple Myeloma: Updated Phase II results and Phase I/II long-term safety; S. Lonial, et al.; Abstract 8542; Poster Discussion Session; June 3, 2013; 1:15 p.m.-5:15 p.m.

ABT-888 (Veliparib)

  • A Phase I Study of Veliparib (ABT-888) in Combination with Carboplatin and Gemcitabine in Subjects with Advanced Solid Tumors; K. M. Bell-McGuinn, et al.; Abstract 2485; Poster Discussion Session; June 3, 2013; 8:00 a.m.-11:45 a.m.

ABT-806

  • A phase I and Biodistribution Study of ABT-806i, an 111 Iindium-Labeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806; H.K. Gan, et al.; Abstract 2520; Poster Discussion Session; June 4, 2013; 8:00 a.m.-12:30 p.m.

About ABT-199

ABT-199 is a selective inhibitor of B-cell lymphoma-2 (BCL-2) proteins. The B-cell lymphoma 2 gene prevents apoptosis of some cells including lymphocytes, and can be highly expressed in cancers in the lymph nodes, spleen, and other organs of the immune system. As a BH3-mimetic, ABT-199 is designed to block the function of the BCL-2 protein by restoring the communication system that tells cancer cells to self-destruct. Jointly developed by AbbVie and Genentech, the companies are pioneering BCL-2 research with ABT-199, which is currently in Phase 1/1b clinical trials for the treatment of CLL, the most common leukemia in the United States, and several other cancers.

The U.S. Food and Drug Administration (FDA) recently accepted AbbVie's amended clinical trial protocols for studies of ABT-199 in patients with CLL and enrollment for ABT-199 clinical trials in CLL, NHL and multiple myeloma has been re-instated. AbbVie and Genentech expect to move ABT-199 into later-stage clinical trials in the near future. 

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs